Showing results (711-720 of 834) with videos related to

Sort By:
Pageof 84
International Journal of Molecular Sciences|May 13, 2026
Intra-Individual Variability of Urinary EGF and Clusterin, and Effect of Frozen Storage on Stability: Results from UVALIDErik Moedt, Rémon Vos, Wenjun Ju, et al.
Diabetes, Obesity & Metabolism|June 15, 2026
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant-Level Exploratory Analysis of the Randomised CONFIDENCE TrialJanet B McGill, Jennifer B Green, Hiddo J L Heerspink, et al.
Eclinicalmedicine|August 13, 2021
Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trialJens Christian Laursen, Niels Søndergaard-Heinrich, Joana Mendes Lopes de Melo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2022
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular diseaseGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.
Kidney International|May 22, 2026
Distinct proteomic signatures of urinary extracellular vesicles link to albuminuria and treatment responses in diabetic kidney diseaseMartijn H van Heugten, Sebastian B Beckmann, Madonna Salib, et al.
Lancet (London, England)|December 18, 2023
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trialKatherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, et al.
JAMA Cardiology|June 3, 2026
Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages: Post Hoc Analysis of the FIDELITY Randomized Clinical TrialsKevin Bryan Lo, John W Ostrominski, Yasuhiro Hamatani, et al.
JACC. Heart Failure|August 27, 2021
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart FailureJohn J V McMurray, David C Wheeler, Bergur V Stefánsson, et al.
Journal of the American Society of Nephrology : JASN|July 17, 2021
Effects of Dapagliflozin in Stage 4 Chronic Kidney DiseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
European Heart Journal|April 1, 2021
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trialHiddo J L Heerspink, C David Sjöström, Niels Jongs, et al.
Pageof 84